Buradasınız

Anasayfa » Content

Aromataz İnhibitörü Tedavisinin Meme Kanserli Hastalarda Serum Total Siyalik Asit Düzeylerine Etkisi

The Effect of Aromatase Inhibitor Therapy on Serum Total Sialic Acid Levels in Breast Cancer Patients

Journal Name:

  • Selçuk Tıp Dergisi

Publication Year:

  • 2010

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
It was reported previously that serum total sialic acid levels were increased in various cancers including breast cancer. We aimed to evaluate the effect of aromatase inhibitor therapy on serum total sialic acid levels in breast cancer patients. Total sialic acid levels were determined in sera of 20 patients with breast cancer and treated with aromatase inhibitors. Total sialic acid levels were determined by a colorimetric method. Serum total sialic acid levels were 15,06±2,71 mmol/ml and 8,17±5,31 mmol/ml at the beginning and three months after the treatment respectively. Thus, a significant decrease in total sialic acid levels was observed after the treatment (p<0,05). We concluded that, aromatase inhibitor therapy results in a significant decrease in sialic acid levels which may be used as a prognostic marker in the treatment of breast cancer.
Bookmark/Search this post with
Abstract (Original Language): 
Meme kanseri de dahil olmak üzere çeşitli kanserlerde serum total siyalik asit düzeylerinde yükselme olduğu daha önce yapılan çalışmalarda bildirilmiştir. Biz meme kanserli hastalarda, aromataz inhibitörü tedavisinin serum total siyalik asit düzeyine etkisini ortaya koymayı amaçladık. Total siyalik asit seviyeleri aromataz inhibitörleriyle tedavi edilen 20 meme kanser tanılı hastada kolorimetrik bir yöntemle ölçüldü. Serum total siyalik asit düzeyleri tedavi başlangıcında ve tedavinin 3. ayında sırasıyla 15,06±2,71 mmol/ml ve 8,17±5,31 mmol/ml olarak bulundu. Böylece tedavi sonrası total siyalik asit düzeylerinde anlamlı bir azalma gözlendi (p<0,05). Aromataz inhibitörü tedavisinin siyalik asit düzeylerinde anlamlı bir düşüşe neden olduğu ve bunun meme kanseri tedavisinde prognostik bir belirteç olarak kullanılabileceği sonucuna vardık.
FULL TEXT (PDF): 
PDF icon arastirmax-aromataz-inhibitoru-tedavisinin-meme-kanserli-hastalarda-serum-total-siyalik-asit-duzeylerine-etkisi.pdf
  • 2
35-37
  • Turkish

REFERENCES

References: 

1- Özmen V. Breast cancer in the world and Turkey. Meme Sağlığı
Dergisi 2008; 4(1):7-12.
2- Eti AF, Gürkan A. Kadınlarda meme kanseri risk düzeyi. Meme
Sağlığı Dergisi 2007;3 (2):63-8.
3- Karamanoğlu YA, Gök ÖF. Mastektomili hastalarda evde bakım.
Meme Sağlığı Dergisi 2008;4(1):3-8.
4- Monica M, Gautam J, David AP. Anastrozole use in early stage
breast cancer of post-menopausal women. Clin Med Ther. 2009
Mar 31;1:141-56.
5- Süer GS, Kazezoğlu C, Tabakoğlu E, Altıay G, Güngör Ö, Türe
M. The importance of serum total and lipid-bound sialic acid
as markers in patients with small cell and non-small cell lung
carcinoma. Trakya Universitesi Tıp Fakültesi Dergisi 2007;
24(2):101-8.
6- Warren L. The thiobarbituric acid assay of sialic acids. J Biol
Chem 1959; 234:1971-5.
7- Celen O, Yildirim E, Ozen N, Sonmez C. Predictive value of
relative changes in serum total sialic acid level for response
to neoadjuvant chemotherapy in patients with locally advanced
breast carcinoma. Neoplasma 2006;53(4):347-51.
8- Stringou E, Chondros K, Kouvaris J, Kakari S, Papavassiliou
K. Serum sialic acid (TSA/LSA) and carcinoembryonic antigen
(CEA) levels in cancer patients undergoing radiotherapy.
Anticancer Res 1992;12(1):251-5.
9- Basoglu M, Atamanalp SS, Yildirgan MI, et al. Correlation
between the serum values of soluble intercellular adhesion
molecule-1 and total sialic acid levels in patients with breast
cancer. Eur Surg Res 2007;39(3):136-40. Epub 2007 Mar 2.
10- López Sáez JJ, Senra-Varela A. Evaluation of lipid-bound sialic
acid (LSA) as a tumor marker. Int J Biol Markers 1995;10(3):174-
9.
11- Balo NN, Ishaq M. Pak J. Serum sialic acid and glycoprotein
levels in some Libyan cancer patients. Pharm Sci 1991;4(1):43-8.
12- O’Kennedy R, Berns G, Moran E, Smyth H, Carroll K, Thornes
RD, O’Brien A, Fennelly J, Butler M. A critical analysis of the
use of sialic acid determination in the diagnosis of malignancy.
Cancer Lett 1991;58(1-2):91-100.
13- Romppanen J, Eskelinen M, Tikanoja S, Mononen I. Total and
lipid-bound serum sialic acid in benign and malignant breast
disease. Anticancer Res 1997;17(2B):1249-53.
14- Patel PS, Raval GN, Rawal RM, Patel MM, Balar DB, Patel DD.
Importance of glycoproteins in human cancer. Indian J Biochem
Biophys 1997;34(1-2):226-33.
15- Patel PS, Baxi BR, Adhvaryu SG, Balar DB. Evaluation of serum
sialic acid, heat stable alkaline phosphatase and fucose as
markers of breast carcinoma. Anticancer Res 1990;10(4):1071-4.
16- Adamo V, Altavilla G, Caristi N, et al. Behavior of serum sialic
acid levels at various stages of neoplastic disease. Minerva Med
1985;76(43):2067-70.
17- Stefenelli N, Klotz H, Engel A, Bauer P. Serum sialic acid
in malignant tumors, bacterial infections, and chronic liver
diseases. J Cancer Res Clin Oncol 1985;109(1):55-9.
18- Dwivedi C, Dixit M, Hardy RE. Plasma sialyltransferase as a
tumor marker. Cancer Detect Prev 1988;11(3-6):191-6.
19- Sönmez H, Süer S, Güngör Z, Baloglu H, Kökoglu E. Tissue
and serum sialidase levels in breast cancer. Cancer Lett
1999;136(1):75-8.

Thank you for copying data from http://www.arastirmax.com